Brief: Assertio Therapeutics to pay $3.6mln over alleged fentanyl product marketing violations, US DOJ says
09/05/2025 16:59
May 9 (Reuters) - Assertio Holdings Inc ASRT.O: US DEPARTMENT OF JUSTICE: ASSERTIO THERAPEUTICS INC. AGREES TO PAY $3.6M TO RESOLVE ALLEGATIONS THAT IT VIOLATED FALSE CLAIMS ACT IN CONNECTION WITH MARKETING ITS FENTANYL PRODUCT Source text: https://tinyurl.com/47b47p4y Further company coverage: ASRT.O (Reporting By Ryan Patrick Jones; editing by Susan Heavey) ((sheavey@thomsonreuters.com;))
Recent news on Assertio Holdings
See all newsBrief: Assertio Announces Completion Of Merger With Zydus Lifesciences And Fundamental Change
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. STOCKS ON THE MOVE -Fervo, Sensata Technologies, Akamai
U.S. STOCKS ON THE MOVE-Chipmakers, Dynatrace, Alibaba